Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

References

• Shimkin MB, Griswold MH, Cutler SJ. Classics in oncology. Survival in untreated and treated cancer. CA Cancer J Clin. 1984;34:282–294.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–1692.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:71–85.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942.
   PubMed Web of Science ®Google Scholar
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–1150.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, et al. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010;116:2081–2089.
   PubMed Web of Science ®Google Scholar
• Knoop AS, Laenkholm AV, Jensen MB, et al. Estrogen receptor, progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer. 2014;50:1412–1421.
   PubMed Web of Science ®Google Scholar
• Yi M, Mittendorf EA, Cormier JN, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer Staging System. J Clin Oncol. 2011;29:4654–4661.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Jensen MB, Burugu S, et al. High-risk premenopausal luminal a breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial. Clin Cancer Res. 2017;23:946–953.
   PubMed Web of Science ®Google Scholar
• Fischerman K, Mouridsen HT. Danish breast cancer cooperative group (DBCG). Present status and experience. Acta Chir Scand Suppl. 1984;519:55–59.
   PubMedGoogle Scholar
• Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506–524.
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization; 1969–1981; Berlin: Springer-Verlag; 1988–present.
   Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
   PubMedGoogle Scholar
• Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004;23:2509–2525.
   PubMed Web of Science ®Google Scholar
• Hähnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979;44:671–675.
   PubMed Web of Science ®Google Scholar
• Aamdal S, Børmer O, Jørgensen O, et al. Estrogen receptors and long-term prognosis in breast cancer. Cancer. 1984;53:2525–2529.
   PubMed Web of Science ®Google Scholar
• Bentzon N, Düring M, Rasmussen BB, et al. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 2008;122:1089–1094.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Yuan Z, Stange KC, et al. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care. 2000;38:411–421.
   PubMed Web of Science ®Google Scholar
• Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54:e55–e64.
   PubMed Web of Science ®Google Scholar
• Mell LK, Jeong JH, Nichols MA, et al. Predictors of competing mortality in early breast cancer. Cancer. 2010;116:5365–5373.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222–5232.
   PubMed Web of Science ®Google Scholar
• Gluz O, Liedtke C, Huober J, et al. EC-Doc investigators (West German Study Group/AGO-B). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2− early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol. 2016;27:1035–1040.
   PubMed Web of Science ®Google Scholar
• Hefti MM, Hu R, Knoblauch NW, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15:R68.
   PubMed Web of Science ®Google Scholar
• Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014.
   PubMed Web of Science ®Google Scholar
• Laenkholm AV, Grabau D, Talman ML, et al. An inter-observer Ki67 reproducibility study applying two different assessment methods. On behalf of the Danish scientific committee of pathology, Danish breast cancer group (DBCG). Acta Oncol. 2018; in press.
   PubMedGoogle Scholar
• Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700–1712.
   PubMed Web of Science ®Google Scholar